Utilized to manage rapid cell division to alleviate joint inflammation and support disease suppression.
Mechanism of Action
Inhibits dihydrofolate reductase, preventing synthesis of tetrahydrofolate required for DNA synthesis inside cellular structures.
Route of Administration
Oral
Onset Time
3–6 weeks
Duration
12–24 hours
Contraindications
Pregnancy, Severe renal impairment, Severe bone marrow suppression, Chronic liver disease
Severe Adverse Events
Severe hepatotoxicity — requires immediate medical attention, Pulmonary fibrosis — requires immediate medical attention, Severe pancytopenia — requires immediate medical attention
Information related to Methotrexate is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
